Drugmakers are likewise reaching out to other employers with the message that treating obesity will ultimately save them money.

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin, at the American Heart Association Scientific ...

Eli Lilly LLY announced that its investigational oral, once-daily cholesterol-lowering drug muvalaplin reduced lipoprotein(a) ...

Merck reported that a new formulation of Keytruda appears to deliver similar blood levels of the drug when given as a shot as ...

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli ...

Lilly’s muvalaplin is the first oral drug to show positive Phase II findings for Lp(a) reduction, eliciting up to an 86% drop ...

Eli Lilly (LLY) Canada Inc. said it is disappointed and strongly disagrees with Canada’s Drug Agency’s Final Recommendation for Ebglyss, published on Friday, November 15, 2024. The CDA-AMC recommended ...

Novo Nordisk has officially launched its weight-loss drug Wegovy in China after receiving approval in June. The move pits it ...

Lilly's drug is the only oral treatment in a field of several injectable therapies being tested to treat high Lp(a), a risk factor for heart disease that affects one in five individuals globally ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...